INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE

Their core work

IPO Porto is Portugal's leading specialized oncology hospital and research center, focused on cancer diagnosis, treatment, and translational research. Their H2020 work centers on precision oncology — from next-generation sequencing (NGS) workflows for personalized cancer therapy to biomarker discovery using extracellular vesicles. They bring clinical oncology infrastructure and patient access to EU research consortia, bridging the gap between laboratory findings and bedside application in cancer care.

What they specialise in

How they've shifted over time

IPO Porto's earliest H2020 involvement (GlyCoCan, 2015) focused on fundamental cancer biology — specifically glycosylation mechanisms in colorectal cancer as part of a training network. By 2019-2020, their focus shifted sharply toward clinical implementation: standardized NGS workflows for personalized therapy (Instand-NGS4P) and exosome-based bio-monitoring (MindGAP). The trajectory shows a clear move from discovery-stage cancer research toward translational tools ready for clinical deployment.

IPO Porto is moving toward implementation-ready precision oncology tools — partners seeking a clinical oncology site for validating NGS diagnostics or liquid biopsy technologies would find strong alignment.

How they like to work

IPO Porto has never coordinated an H2020 project, participating instead as a partner or third party — consistent with their role as a specialized clinical center contributing patient data, clinical validation, and oncology expertise to larger consortia. With 44 unique partners across 14 countries from just 3 projects, they operate within large, diverse networks. This suggests they are a valued clinical endpoint in multi-site studies rather than a project initiator.

Despite only 3 projects, IPO Porto has collaborated with 44 partners across 14 countries, indicating participation in large pan-European consortia. Their network is broadly European with no obvious geographic concentration.

What sets them apart

IPO Porto is one of Portugal's few dedicated comprehensive cancer centers, giving it direct access to oncology patient cohorts and clinical infrastructure that most university hospitals cannot match. For consortium builders, they offer a rare combination: a public oncology hospital that actively engages in EU research, providing real-world clinical validation for cancer diagnostics and therapeutics. Their involvement in both genomics standardization (Instand-NGS4P) and exploratory biomarker research (MindGAP) shows versatility across TRL levels.

Highlights from their portfolio

• Instand-NGS4P
  A Pre-Commercial Procurement (PCP) project standardizing NGS workflows for personalized cancer therapy — directly addresses regulatory readiness (IVDR) and clinical deployment across pediatric and adult oncology.
• MindGAP
  Their largest funded project (EUR 793,525), exploring the unconventional intersection of exosomes, plastic antibodies, and mind-body interaction for personalized medicine — a distinctive research direction for a cancer hospital.